NEEDS REVIEW
As of November 19, 2026 at 6:17 PM, this is how Optics News reads the wording differences in this story.
What happened It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
The headline split The headlines are mostly aligned. The differences are small wording choices, not a major framing split.
Match confidence Developing. Only 2 sources are matched, and the source map is still narrow. Useful to watch, not enough to draw conclusions yet.
Same-event confidenceDevelopingNot enough sources yet to confirm this is the same specific event.
Framing confidenceHiddenWording-gap score not shown — same-event match is still developing.
Wording differs, but the match is too narrow to read confidently yet.
WHAT EACH SIDE EMPHASIZED
Left / center-leftNo matching source in this bucket yet.Optics keeps watching for pickup.
CenterThe GLP-1 blind spot: Why the FDA’s new eye stroke warning mattersThe Hill · Center · News report
Right / center-rightNo matching source in this bucket yet.Optics keeps watching for pickup.
SEE THE HEADLINES
The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
Open sourceThe GLP-1 blind spot: Why the FDA's new eye stroke warning matters
The Food and Drug Administration's on GLP-1 drugs should serve as a wake-up call for patient safety and corporate accountability.
Open sourceDetailsScore hidden · 2 sources · 1 bias buckets
Score hidden until the match is cleanerLow confidence2 sources · 1 bias bucketsDeveloping · 2 sources · 1 bucketFormats: News report
SOURCE MAP CHANGES
Nov 19, 5:30 PM: The Hill joined the source map.
Nov 19, 6:17 PM: AllSides joined the source map.
Now: score hidden until the source match is cleaner. Story health is developing · 2 sources · 1 bucket.